Cytokinetics, Incorporated (CYTK) vs Danaher Corporation (DHR)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CYTK | DHR | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Diagnostics & Research |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | rare-disease | life-science-tools |
| Price and returns | ||
| Last close | $60.73 | $232.97 |
| Return · 1 week | −3.06% | +3.81% |
| Return · 1 month | −8.21% | +2.66% |
| Return · 3 months | −23.56% | +17.04% |
| Return · year to date | −1.62% | +1.33% |
| Return · 1 year | +0.91% | +5.78% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −31.23% | −4.05% |
| 52-week high | $88.31 | $242.80 |
| 52-week low | $54.30 | $160.93 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $8.51B | $163.77B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $105.71M | $834.36M |
| Employees | 673 | 58,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 39.18× |
| Price to earnings · forward | n/a (negative forward earnings) | 23.64× |
| Price to sales | 127.27× | 6.15× |
| Price to book | n/a (negative book value) | 2.94× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 22.06× |
| Enterprise value to revenue | 131.10× | 7.05× |
| PEG ratio | — | 1.29 |
| Earnings per share · trailing | -7.22 | 5.61 |
| Profitability | ||
| Gross margin | — | 58.51% |
| Operating margin | −625.95% | 19.78% |
| Profit margin | −1321.12% | 15.89% |
| Return on equity | — | 7.61% |
| Return on assets | −28.09% | 3.95% |
| Growth | ||
| Revenue growth | −57.10% | +5.50% |
| Earnings growth | — | +59.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 52.97 |
| Current ratio | 6.66 | 1.65 |
| Dividend yield | 0.00% | 0.74% |
| Payout ratio | 0.00% | 25.67% |
| Trend and volatility | ||
| RSI · 14 | 35.08 | 62.01 |
| ADX · 14 | 27.94 | 31.94 |
| 50-day average | $68.66 | $216.74 |
| 200-day average | $70.11 | $201.19 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.28% | 2.78% |
The full CYTK analysis
Everything this table leaves out for Cytokinetics, Incorporated: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CYTK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CYTK analysisThe full DHR analysis
Everything this table leaves out for Danaher Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DHR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DHR analysis